Haemonetics (HAE) Gross Profit (2009 - 2026)

Haemonetics has reported Gross Profit for 18 years, with the latest figure at $202.8 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 5.49% year-over-year to $202.8 million in Q2 2026; TTM through Jun 2026 was $798.1 million, a 4.16% increase from a year earlier, with the FY2026 full-year figure at $787.6 million, up 5.16% from the prior year.
• Gross Profit was $202.8 million for Q2 2026 at Haemonetics, up from $198.2 million in the prior quarter.
• The five-year high for Gross Profit was $202.8 million in Q2 2026, with the low at $136.3 million in Q2 2022.
• Average Gross Profit over 5 years is $174.8 million, with a median of $175.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Gross Profit jumped 66.63% in 2022, then advanced 2.67% in 2026.
• Over 5 years, Gross Profit stood at $158.7 million in 2022, then gained by 12.07% to $177.9 million in 2023, then grew by 8.82% to $193.5 million in 2024, then climbed by 4.57% to $202.4 million in 2025, then advanced by 0.21% to $202.8 million in 2026.
• The last three Gross Profit figures came in at $202.8 million (Q2 2026), $198.2 million (Q1 2026), and $202.4 million (Q4 2025), per Business Quant data.